2658-6533Research Results in Biomedicine2658-653310.18413/2313-8955-2015-1-3-89-96478Archive categoriesCOMPARATIVE EVALUATION OF HIXOZIDE IN RESPIRATORY TUBERCULOSISCOMPARATIVE EVALUATION OF HIXOZIDE IN RESPIRATORY TUBERCULOSISMaslennikovAndrey A.MaslennikovAndrey A.ObolonkovaNatalya I.ObolonkovaNatalya I.obolonkova@bsu.edu.ru20151300

The authors have conducted an open comparative study of the efficacy and safety of Hixozide. The study included 30 patients with pulmonary tuberculosis, who for 21 days in addition to the combination of TB chemotherapy received Hixozide inhalations in accordance with the instructions for use. Significant positive dynamics of clinical, radiologic and endoscopic manifestations of tuberculosis were observed in the majority of patients − 78.6%, in 10.7% with a complete cure of bronchial tuberculosis. All patients with concomitant nonspecific endobronchitis (33.3%) during the treatment with Hixozide marked relief of nonspecific inflammation, reducing the amount and viscosity of sputum. Subclinical signs of toxicity were found. The results of the study indicate the efficacy and good tolerance of Hixozide in the complex treatment of patients with bronchial tuberculosis.

The authors have conducted an open comparative study of the efficacy and safety of Hixozide. The study included 30 patients with pulmonary tuberculosis, who for 21 days in addition to the combination of TB chemotherapy received Hixozide inhalations in accordance with the instructions for use. Significant positive dynamics of clinical, radiologic and endoscopic manifestations of tuberculosis were observed in the majority of patients − 78.6%, in 10.7% with a complete cure of bronchial tuberculosis. All patients with concomitant nonspecific endobronchitis (33.3%) during the treatment with Hixozide marked relief of nonspecific inflammation, reducing the amount and viscosity of sputum. Subclinical signs of toxicity were found. The results of the study indicate the efficacy and good tolerance of Hixozide in the complex treatment of patients with bronchial tuberculosis.

pulmonary tuberculosischemotherapyHixozidepulmonary tuberculosischemotherapyHixozideСписок литературы1. Astakhov A.V., Lepakhin V.K. Medicines: Adverse Side Effects and Safety Control. 2nd ed. M .: Eksmo, 2008.2. Borisov S.E., Ivanushkina T.N., Litvinova N.V. How to Improve the Etiotropic Treatment of Tuberculosis Patients // In. scientific. works of the 70th anniversary of VI Litvinov. M .: MNPTSBT, 2011. Pp. 70-97.3. Ivanovа D.A., Borisov S.E., Ryzhov A.M. The Frequency and Risk of Developing Severe Adverse Reactions in the Treatment of new TB Cases // Tuberculosis. 2012. № 12. Pp. 15-22.4. Mishin V.Yu, Chukanov V., Grigoriev Y.G. Side Effects of TB Drugs in Standard and Customized Regimens. Moscow, 2004. 206 p.5. Sokolova G.B., Wiesel A.A. TB Drugs // In .: Phthisiology. National Leadership / Ed. MI Pe-relmana. M., 2007. Pp. 414-416.6. Burman W., Gallicano K., Peloquin C. Comparative pharmacokinetics and pharmacologists of the antibacterials // Clin. Pharmacokinetic. 2001. Vol. 40.  Pp. 327-341.7. Fox W., Ellard G., Mitchison D. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications // Int. J. Tuberc. Lung Dis.  1999.  Vol. 3.  P. 231-279.8. Ginsberg A. Tuberculosis drug development: progress, challenges, and the road ahead // Tuberculosis (Edinb). 2010. Vol. 90, № 3.  P. 162-167.9. Mitnick C., McGee B., Peloquin C. Tuberculosis pharmacotherapy: strategies to optimize patient care // Expert Opin. Pharmacother. 2009. Vol. 10, № 3. P. 381-401.